The European Life Sciences team advised Advanced Medical Solutions Group plc (AIM: AMS) on its acquisition of Sealantis Limited for $25 million (approximately £19 million) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.
Established in 1991, Advanced Medical Solutions Group is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, silver alginates, alginate and foams which it markets under its brands; LiquiBand®, RESORBA® and ActivHeal®, as well as supplying under white label.
The Goodwin team was led by partner Sophie McGrath.
For additional details on the acquisition, please read the press release.